---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268057"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:58:31.779755+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q3 revenue $13.1M (+41% YoY); net loss narrows; IND cleared for VYD2311

## Summary
- PEMGARDA net product revenue $13.1M in Q3 2025, up 41% YoY and 11% QoQ.
- Net loss $10.5M ($0.06 diluted EPS) vs $60.7M ($0.51) in Q3 2024; R&D spend fell to $8.0M from $57.9M.
- Cash $85.0M at Sep 30; >$100M after Oct ATM; $57.5M gross proceeds from Aug 2025 offering.
- FDA cleared IND for VYD2311; pivotal REVOLUTION program (DECLARATION N=1770, LIBERTY N=210) starts near year-end 2025, data mid-2026.
- Board adds Dr. Paul Bolno; Kristie Kuhl named CCO; pipeline expansion into RSV and measles.

## SEC filing metadata
- accession: 0001193125-25-268057
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/0001193125-25-268057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/d81968d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268057
- JSON: https://secwatch.observer/filing/0001193125-25-268057.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.